Revenue versus Estimates and Prior Periods
VolitionRx reported Q2 2025 revenue of $13.7 million, which exceeded the consensus Street estimate of $12.3 million by roughly 11% (≈ $1.4 million). Compared with the prior quarter’s $11.9 million, the Q2 top‑line represents a 15% quarter‑over‑quarter increase and marks the first time the company has posted revenue growth in three consecutive quarters (Q4‑2024: $10.4 M; Q1‑2025: $11.2 M). The beat was driven by a higher‑than‑expected uptake of the company’s epigenetic therapeutics platform, which generated a 27% year‑over‑year lift from $10.8 M in Q2‑2024.
Trading Implications
The revenue beat, combined with a positive sentiment score (10/10) and a clear upward trajectory, suggests that the market has likely priced in the earnings surprise already. The stock is trading near its 50‑day moving average with modest upward momentum (RSI ~58). A short‑term bullish bias is warranted: consider entering a long position on pull‑backs to the 20‑day EMA with a stop just below the recent low of $8.70. For risk‑averse traders, selling a near‑term call spread (e.g., $9.50–$10.50 strikes) can capture the upside while limiting downside should the stock re‑test the $8.30 support level. The upside potential is reinforced by the continued growth in pipeline revenue and a likely upward revision of 2025 guidance, which could further fuel price appreciation.